Since different tauopathies are characterized by the formation of distinct tau fibril morphologies, it is important to combine the search of tau aggregation inhibitors with the development of in vitro tau aggregation assays that recapitulate aggregation as it may occur in the brain. The gene discussed is MAPT; the disease is tauopathy.